DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Campania Luigi Vanvitelli
About this trial
The goal of this observational study is to evaluate if there are differences in DNA methylation of peripheral blood in patients with Brugada syndrome and healthy subjects. The main question it aims to answer is:
Does DNA methylation changes distinguish Brugada patients from healthy controls?
Does DNA methylation changes distinguish Brugada patients with high versus low risk of sudden cardiac death?
Eligibility criteria
Qualifiers
Brugada syndrome was confirmed when the 12-lead ECG showed ST-segment elevation with a type-1 morphology of ≥2 mm in ≥1 right precordial lead either spontaneously or after a provocative drug test (intravenous administration of a Class I antiarrhythmic) in the absence of any structural heart disease.
>18 years
Unrelated patients
Disqualifiers
Related patients
Not type 1 Br patter
Trial design
Treatments tested in this trial
- Not listed
Trial groups
10 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov